Skip to main content

Advertisement

Log in

How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

The idea of model-based drug development championed by Lewis Sheiner, in which pharmacostatistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers a quantitative approach to improving drug development and development decision-making. Examples are presented that support this paradigm. The first example describes a preclinical model of behavioral activity to predict potency and time-course of response in humans and assess the potential for differentiation between compounds. This example illustrates how modeling procedures expounded by Lewis Sheiner provided the means to differentiate potency and the lag time between drug exposure and response and allow for rapid decision making and dose selection. The second example involves planning a Phase 2a dose-ranging and proof of concept trial in Alzheimer’s disease (AD). The issue was how to proceed with the study and what criteria to use for a go/no go decision. The combined knowledge of AD disease progression, and preclinical and clinical information about the drug were used to simulate various clinical trial scenarios to identify an efficient and effective Phase 2 study. A design was selected and carried out resulting in a number of important learning experiences as well as extensive financial savings. The motivation for this case in point was the “Learn-Confirm” paradigm described by Lewis Sheiner. The final example describes the use of Pharmacokinetic and Pharmacodynamic (PK/PD) modeling and simulation to confirm efficacy across doses. In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia. The clinical trial data was not replicated for each of the sought dose levels in the drug application presenting a regulatory dilemma. Exposure response analysis submitted in the New Drug Application was applied to confirm the evidence of efficacy across these dose levels. Modeling and simulation analyses showed that the two studies corroborate each other with respect to the pain relief profiles. The use of PK/PD information confirmed evidence of efficacy across the three studied doses, eliminating the need for additional clinical trials and thus supporting the approval of the product. It can be speculated that the work by Lewis Sheiner reflected in the FDA document titled “Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products” made this scientific approach to the drug approval process possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. L.B. Sheiner (1997) ArticleTitleLearning versus confirming in clinical drug development Clin. Pharmacol. Ther. 61 275–291 Occurrence Handle10.1016/S0009-9236(97)90160-0 Occurrence Handle9084453 Occurrence Handle1:STN:280:ByiB3sfhtFM%3D

    Article  PubMed  CAS  Google Scholar 

  2. Food and Drug Administration. Innovation; Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. 2004.

  3. L.B. Sheiner D.R. Stanski S. Vozeh R.D. Miller (1979) ArticleTitleJ. Ham Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin. Pharmacol. Ther. 25 358–371 Occurrence Handle761446 Occurrence Handle1:CAS:528:DyaE1MXhsl2qsro%3D

    PubMed  CAS  Google Scholar 

  4. S.L. Beal L.B. Sheiner (1998) NONMEM Users Guide NONMEM project group University of California San Francisco

    Google Scholar 

  5. R. Miller J.D. Hermann W. Ewy K.G. Kowalski (2004) The strategic role and application of pharmacokinetic/pharmacodynamic modeling in drug development P.L. Bonate D.R Howard (Eds) Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, Vol 1. AAPS Press Arlington VA 551–581

    Google Scholar 

  6. N.H.G. Holford K.E. Peace (1992a) ArticleTitleMethodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer’s patients treated with tacrine Proc. Natl. Acad. Sci. USA. 89 11466–11470 Occurrence Handle1:CAS:528:DyaK3sXntlGgsQ%3D%3D

    CAS  Google Scholar 

  7. N.H.G. Holford K.E. Peace (1992b) ArticleTitleResults and validation of a population pharmacodynamic model for cognitive effects in Alzheimer’s patients treated with tacrine Proc. Natl. Acad. Sci. USA. 89 11471–11475 Occurrence Handle1:CAS:528:DyaK3sXntlGgtg%3D%3D

    CAS  Google Scholar 

  8. N.H.G. Holford K.E. Peace (1994) ArticleTitleThe effect of tacrine and lecithin in Alzheimer’s disease A population pharmacokinetic analysis of five clinical trials. Eur. J. Clin. Pharm. 47 17–23 Occurrence Handle1:STN:280:ByqD1c%2FjtF0%3D

    CAS  Google Scholar 

  9. Federal Food, Drug and Cosmetic Act of 1938, Drug Amendments of 1962. Pub. L. No. 87–781, 76 Stat. 780 (1962)

  10. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105–115, 111 Stat. 2295 (1997).

  11. Guidance for Industry: Exposure-response relationships, study design, data analysis and regulatory applications. Food and Drug Administration, May 2003, Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Food and Drug Administration, May 1998.

  12. B. Frame P. Burger R. Miller J. Cook E. Garafolo L. Knapp H.N. Bockbrader B.W. Corrigan (2001) An Analysis of Exposure Response data for Gabapentin for the Treatment of Neuropathic Pain Neuropathic Pain Meeting San Francsico

    Google Scholar 

  13. Neurontin® (Parke-Davis) Capsules. Physicians Desk Reference Electronic Library™ Online: ©2002. Thomson MICROMEDEX.

  14. C.C. Peck D.B. Rubin L.B. Sheiner (2003) ArticleTitleHypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval Clin. Pharmacol. Ther. 73 481–490 Occurrence Handle10.1016/S0009-9236(03)00018-3 Occurrence Handle12811358

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Raymond Miller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, R., Ewy, W., Corrigan, B.W. et al. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development. J Pharmacokinet Pharmacodyn 32, 185–197 (2005). https://doi.org/10.1007/s10928-005-0074-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-005-0074-7

Keywords

Navigation